Smarter. Faster. Intuitive.
Meet Aika
The AI platform accelerating clinical trials
Aika is the first AI-native platform for clinical trials, unifying solutions for protocol design, feasibility, and regulatory planning in one intuitive workspace. It helps clinical teams accelerate trial setup, reduce risk, and bring treatments to patients faster.
AI-accelerated protocol creation, feasibility, and alignment.
Accelerated design
AI-accelerated protocol creation, feasibility, and alignment.
Amendment prevention
AI-accelerated protocol creation, feasibility, and alignment.
100% explainable decisions
AI-accelerated protocol creation, feasibility, and alignment.
Based on
~1 million real trials
Testimonials
Trusted by leaders. Backed by science.
Based on ~1 million real trials.
“Biorce is exactly the kind of pioneering company we’re here to back. They’re combining deep sector expertise with cutting-edge AI to solve what truly matters. Their platform has the potential to radically reduce both the time and cost of bringing new treatments to market, unlocking huge value for pharma and, more importantly, faster access to life-saving therapies for patients.”
Tove Larsson
General Partner | Norrsken VC
"The suggested protocol is quite close to the one we finalized… around 60–70% similarity."
Verified Customer
Used across US, EU & APAC by global clinical trial teams.
"The expansive potential of Jarvis hints at a wealth of untapped applications beyond drugs development; it opens the door to evolutionary possibilities that could help redefine efficiency and precision in the broader medical field"
Ricardo Matias
CRIO | Co-Founder of Kinetikos
“Feasibility speed increased by 32% and amendment reduction was 50%. For a $50K trial, we save $5–8K on setup and $10–20K on fewer amendments."
Verified Customer
Built by former CRO, clinicians, regulatory, and AI leaders.
52M from DST Global, Europe’s leading impact VC to reinvent clinical trials.
"I think this is a fantastic tool for clinical trialists that will not only save time but could potentially reduce the number of avoidable protocol amendments, saving costs and enhancing confidence in evaluation of the study objectives"
Laurence Skillern
Medical Director | CMO of ISTESSO
"This feels like chatting with a trial assistant. First truly AI-native tool with conversational workflow, not requiring IT affinity or coding."
Verified Customer
Due to confidentiality, some customer references are anonymized.